CA 15-3 measurement

Henry JB: Clinical Diagnosis and Management by Laboratory Methods, 20th ed. Saunders, 2001.

Zimmerman RL MD, Fogt F MD, & Goonewardene S MD: Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions. Cancer 2000; 90:230-234.

Tietz NW (Ed): Clinical Guide to Laboratory Tests, 3rd ed. W. B. Saunders, Philadelphia, PA, 1995.

Duffy MJ, Duggan C, Keane R, et al: High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004; 50(3):559-563.

Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.. J Clin Oncol. 2001; 19:1865-78.

Bast RC Jr, Ravdin P, Hayes DF, et al: Erratum to 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19(21):4185-4188.

Shering SG, Sherry F, McDermott EW, et al: Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer 1998; 83(12)::2521-2527.